Gena Wang
Stock Analyst at Barclays
(3.05)
# 1,202
Out of 5,246 analysts
238
Total ratings
42.5%
Success rate
0.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Maintains: Overweight | $37 → $12 | $6.35 | +88.98% | 8 | May 15, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $87 → $95 | $76.94 | +23.47% | 7 | Apr 6, 2026 | |
| LEGN Legend Biotech | Maintains: Overweight | $90 → $80 | $29.37 | +172.39% | 8 | Feb 4, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $81 → $50 | $23.39 | +113.77% | 7 | Nov 24, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $8.60 | +283.72% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $46.88 | -46.67% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $12.60 | +11.11% | 9 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $68.81 | -1.18% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $16.80 | +19.05% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $434.52 | -4.72% | 18 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $9 | $6.62 | +35.95% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $8.29 | +8.56% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $297.45 | +77.17% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $75.56 | +25.73% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $54.09 | +47.90% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $3.50 | +128.57% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $36.23 | -53.08% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $59 → $62 | $13.07 | +374.37% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $50.36 | +11.20% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $28.64 | -26.68% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $9.19 | +237.32% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.76 | +8.70% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $25.61 | -64.86% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $7.03 | +255.62% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $9.24 | +94.81% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $7.08 | +27.12% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.44 | +4,955.15% | 1 | Jan 6, 2017 |
REGENXBIO
May 15, 2026
Maintains: Overweight
Price Target: $37 → $12
Current: $6.35
Upside: +88.98%
Cytokinetics
Apr 6, 2026
Maintains: Overweight
Price Target: $87 → $95
Current: $76.94
Upside: +23.47%
Legend Biotech
Feb 4, 2026
Maintains: Overweight
Price Target: $90 → $80
Current: $29.37
Upside: +172.39%
Ultragenyx Pharmaceutical
Nov 24, 2025
Maintains: Overweight
Price Target: $81 → $50
Current: $23.39
Upside: +113.77%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $8.60
Upside: +283.72%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $46.88
Upside: -46.67%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $12.60
Upside: +11.11%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $68.81
Upside: -1.18%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $16.80
Upside: +19.05%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $434.52
Upside: -4.72%
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $6.62
Upside: +35.95%
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $8.29
Upside: +8.56%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $297.45
Upside: +77.17%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $75.56
Upside: +25.73%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $54.09
Upside: +47.90%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $3.50
Upside: +128.57%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $36.23
Upside: -53.08%
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $13.07
Upside: +374.37%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $50.36
Upside: +11.20%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $28.64
Upside: -26.68%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $9.19
Upside: +237.32%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.76
Upside: +8.70%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $25.61
Upside: -64.86%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $7.03
Upside: +255.62%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $9.24
Upside: +94.81%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $7.08
Upside: +27.12%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.44
Upside: +4,955.15%